Y-mAbs Therapeutics A/S: Financial statements 2020
CVR: 37053678
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
Y-mAbs Therapeutics A/S (CVR 37053678) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK 82,433,523 and a net result of DKK -1,202,417 compared with DKK -2,579,400 the year before. That is an increase of 58.4% compared with the year before. Equity in the 2020 report amounted to DKK 2,832,657. The solvency ratio was 5.4%. The company had 62 employees in the financial year.
- Gross Profit
- DKK 82,433,523
- Profit/Loss
- DKK -1,202,417
- Equity
- DKK 2,832,657
- Total Assets
- DKK 52,037,670
- Employees
- 62
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | 82.4M | -1.2M | 2.8M | 62 |
| 2019 | - | 52M | -2.6M | 4M | 36 |
| 2018 | - | 28.6M | -4.2M | 1.6M | 19 |
| 2017 | - | 13.2M | -2.2M | 808K | - |
Official annual report
How creditworthy is Y-mAbs Therapeutics A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of June 11, 2020, Laura J. Hamill has joined the board of directors of Y-mAbs Therapeutics A/S.
As of June 11, 2020, Gregory Stephen Raskin has left the board of directors of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2019. Gross profit came to DKK 52,032,447, and the net result was DKK -2,579,400.
About Y-mAbs Therapeutics A/S
Y-mAbs Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Vincent Sainte-Catherine. The board consists of Antoine Bernasconi (chair), Julien Forest and Vincent Sainte-Catherine. The company is owned by Y-mAbs Therapeutics, Inc.. The company has 13 employees (2026). In 2025, the company reported a gross profit of DKK 29,300,371 and a net result of DKK -38,461,598 compared with DKK -12,500,464 the year before. Equity in the 2025 report amounted to DKK -163,651,844.
